Tohoku University Nanoparticles Conquer Drug-Resistant Cancer

In a groundbreaking advancement from Tohoku University's Graduate School of Pharmaceutical Sciences, researchers have engineered porous amino acid nanoparticles designed to outsmart drug-resistant cancer cells. This innovation addresses one of the most formidable challenges in oncology: multidrug resistance (MDR), where cancer cells expel chemotherapy drugs like doxorubicin before they can inflict damage. The new nanoparticles not only deliver the drug more effectively but also incorporate a sequential release mechanism and photothermal therapy, offering a multi-pronged attack on resilient tumors.

The development highlights Tohoku University's prowess in nanomedicine, a field where Japanese higher education institutions continue to lead globally. With cancer remaining Japan's leading cause of death—projected to see over 1 million new cases in 2026 according to the National Cancer Center Japan—this research could transform treatment paradigms at universities and hospitals nationwide.

The Challenge of Drug-Resistant Cancer in Japan

Multidrug resistance arises primarily from overexpression of P-glycoprotein (P-gp), an ATP-binding cassette transporter that pumps anticancer agents out of cells, rendering treatments like doxorubicin ineffective. Doxorubicin, or Dox, is an anthracycline antibiotic widely used for breast, lung, and ovarian cancers, but resistance develops in up to 50% of advanced cases worldwide, including in Japan where chemotherapy failure contributes to high recurrence rates.

At Tohoku University, Professor Eijiro Miyako's team recognized that conventional approaches fail because they do not first neutralize the cell's expulsion mechanism. Their solution: nanoparticles that release a P-gp inhibitor before the therapeutic drug, mimicking the strategy of 'patching a hole in a leaky bucket before adding water.' This sequential delivery ensures Dox accumulates intracellularly, maximizing cytotoxicity.

Engineering the Porous Amino Acid Nanoparticles

The nanoparticles are fabricated from biocompatible amino acid-derived materials via a self-templating method, creating a porous structure ideal for drug loading. They encapsulate doxorubicin and quinidine (Qui), a potent P-gp inhibitor. The surface is coated with indocyanine green (ICG), a near-infrared (NIR) dye approved for clinical use, enabling photothermal therapy (PTT).

The process unfolds in stages: upon reaching the tumor via enhanced permeability and retention (EPR) effect, NIR laser irradiation (808 nm) triggers ICG to generate heat (up to 50°C), disrupting cell membranes and promoting Qui release. Qui then inhibits P-gp within minutes, followed by Dox release over hours, overwhelming the now-vulnerable cancer cells. Active targeting via ICG's affinity for tumor vasculature further enhances specificity.

This design leverages Tohoku's expertise in microfluidic synthesis and biomaterials, honed over years in the Graduate School of Pharmaceutical Sciences.

Research Team and International Collaboration

Leading the effort is Professor Eijiro Miyako, a pioneer in nanotherapeutics at Tohoku University, also a Visiting Professor at Japan Advanced Institute of Science and Technology (JAIST). Co-authors Tengfei Wang and Nina Sang from Tohoku collaborated with Cécilia Ménard-Moyon and Alberto Bianco from France's CNRS and University of Strasbourg, underscoring Japan's global research networks.

The study, published May 6, 2026, in the Journal of Controlled Release (DOI: 10.1016/j.jconrel.2026.114954), exemplifies interdisciplinary work between chemistry, pharmacology, and engineering at Tohoku.

Promising Results from Lab and Animal Studies

In vitro tests on MDR human breast cancer cells (MCF-7/ADR) showed the nanoparticles combined with PTT eradicated over 90% of cells, far surpassing Dox or PTT alone. Intracellular Dox levels rose 5-fold due to P-gp inhibition.

In vivo, subcutaneous MDR tumors in mice regressed completely after three nanoparticle injections and NIR sessions. Tumor volumes dropped to undetectable levels by day 20, with 100% survival at 40 days versus 0% in controls. No systemic toxicity was observed, as confirmed by histopathology.

These outcomes position the technology for preclinical optimization toward clinical trials.

Tohoku University's Leadership in Nanomedicine

Tohoku University, located in Sendai, ranks among Japan's top institutions for pharmaceutical sciences, with its Graduate School fostering innovations in drug delivery. Professor Miyako's lab specializes in multifunctional nanomaterials, building on prior work like bacteria-boosted nanoparticles for immunotherapy. The university's Advanced Institute for Materials Research (AIMR) supports such interdisciplinary efforts, attracting international talent.

This breakthrough aligns with Tohoku's mission to translate basic research into societal impact, particularly in oncology where Japan faces rising MDR challenges amid an aging population.

Japan's Higher Education Ecosystem in Cancer Nanotechnology

Japanese universities dominate nanotech cancer research. The University of Tokyo and Kyoto University lead in nanoparticle design, with ongoing trials for silica-based carriers. JAIST, Kyushu University, and Osaka University contribute to photothermal agents and targeted delivery.

Government funding via AMED and JST has poured billions into precision medicine, enabling collaborations like Miyako's with European partners. Programs at national universities train PhD students in microfluidics and bioconjugation, preparing a new generation for biotech careers.Tohoku University press release

Challenges, Implications, and Future Directions

While promising, scalability, long-term biocompatibility, and human trials remain hurdles. Regulatory approval in Japan via PMDA could accelerate translation given ICG's established safety.

Implications extend beyond breast cancer to lung and ovarian types prevalent in Japan. By reviving Dox efficacy, costs drop—Dox generics are affordable—and side effects minimize through targeting. Future iterations may incorporate gene therapy or immunotherapy.

Miyako envisions: 'This could become a beacon of hope for cancer patients.' At Tohoku, next steps include optimizing for clinical-grade production.

Career Opportunities in Japanese Pharmaceutical Research

This innovation spotlights opportunities at Tohoku and peers. Postdocs in nanomedicine earn ¥5-7 million annually, with faculty tracks offering stability. Programs like JSPS fellowships support international researchers.

Japan's universities emphasize hands-on training, ideal for PhDs transitioning to pharma giants like Takeda or startups in Sendai's biotech hub. Explore roles in drug formulation and oncology.

• Postdoctoral positions in nanoparticle synthesis
• Assistant professor openings in pharmaceutical sciences
• Collaborative projects with CNRS/Europe

Photo by Chaojie Ni on Unsplash

Broader Impact on Japanese Higher Education

Such breakthroughs reinforce Japan's R&D investment, with universities contributing 70% of nanotech patents. Tohoku's model—integrating education, research, and industry—trains 500+ pharma grads yearly, addressing Japan's doctor shortage while advancing global health.

Student involvement in Miyako's lab via master's theses fosters innovation, preparing graduates for roles at RIKEN or abroad.